CL2022003400A1 - Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette - Google Patents

Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette

Info

Publication number
CL2022003400A1
CL2022003400A1 CL2022003400A CL2022003400A CL2022003400A1 CL 2022003400 A1 CL2022003400 A1 CL 2022003400A1 CL 2022003400 A CL2022003400 A CL 2022003400A CL 2022003400 A CL2022003400 A CL 2022003400A CL 2022003400 A1 CL2022003400 A1 CL 2022003400A1
Authority
CL
Chile
Prior art keywords
treatment
phosphodiesterase inhibitor
tourette syndrome
syndrome
subject
Prior art date
Application number
CL2022003400A
Other languages
English (en)
Spanish (es)
Inventor
George Garibaldi
Original Assignee
Noema Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma Ag filed Critical Noema Pharma Ag
Publication of CL2022003400A1 publication Critical patent/CL2022003400A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CL2022003400A 2020-06-05 2022-12-01 Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette CL2022003400A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035310P 2020-06-05 2020-06-05
US202163160302P 2021-03-12 2021-03-12

Publications (1)

Publication Number Publication Date
CL2022003400A1 true CL2022003400A1 (es) 2023-07-28

Family

ID=76325557

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022003400A CL2022003400A1 (es) 2020-06-05 2022-12-01 Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette
CL2025002636A CL2025002636A1 (es) 2020-06-05 2025-08-29 Uso inhibidor de pde10 para tratamiento del síndrome de tourette (divisional de solicitud no. 202203400)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2025002636A CL2025002636A1 (es) 2020-06-05 2025-08-29 Uso inhibidor de pde10 para tratamiento del síndrome de tourette (divisional de solicitud no. 202203400)

Country Status (13)

Country Link
US (2) US11883385B2 (enExample)
EP (1) EP4161526A1 (enExample)
JP (2) JP7748974B2 (enExample)
KR (2) KR20250171459A (enExample)
CN (2) CN121891333A (enExample)
AU (1) AU2021285225B2 (enExample)
BR (1) BR112022024751A2 (enExample)
CA (1) CA3180793A1 (enExample)
CL (2) CL2022003400A1 (enExample)
IL (2) IL327564A (enExample)
MX (1) MX2022015400A (enExample)
PH (1) PH12023550007A1 (enExample)
WO (1) WO2021245280A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12544364B2 (en) * 2020-06-05 2026-02-10 Noema Pharma Ag Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
JP2024505515A (ja) * 2021-01-28 2024-02-06 ノエマ ファーマ アクツィエンゲゼルシャフト 小児期発症流暢症の治療のための方法
WO2026068583A1 (en) * 2024-09-25 2026-04-02 Noema Pharma Ag Use of phosphodiesterase 10 inhibitor gemlapodect for weight loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
EP1723134A2 (en) * 2004-02-18 2006-11-22 Pfizer Products Incorporated Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US8349824B2 (en) 2010-12-07 2013-01-08 Hoffmann-La Roche Inc. Triazolopyridine compounds
CA2845578C (en) * 2011-08-25 2016-02-16 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
EP4616915A3 (en) * 2012-07-12 2025-12-17 Emalex Biosciences, Inc. Ecopipam for treatment of tourettes syndrome
TR201904614T4 (en) * 2013-02-27 2019-05-21 Mochida Pharm Co Ltd Novel pyrazole derivative.
CN105164126B (zh) * 2013-04-30 2017-05-31 豪夫迈·罗氏有限公司 吡唑酰胺的Pd‑催化偶联

Also Published As

Publication number Publication date
KR20230040978A (ko) 2023-03-23
US11883385B2 (en) 2024-01-30
KR20250171459A (ko) 2025-12-08
CA3180793A1 (en) 2021-12-09
EP4161526A1 (en) 2023-04-12
WO2021245280A9 (en) 2022-01-27
WO2021245280A1 (en) 2021-12-09
CN116137811A (zh) 2023-05-19
BR112022024751A2 (pt) 2023-03-07
MX2022015400A (es) 2023-03-16
US20230149372A1 (en) 2023-05-18
IL298713B1 (en) 2026-05-01
IL298713A (en) 2023-02-01
JP2025183391A (ja) 2025-12-16
PH12023550007A1 (en) 2024-03-11
JP7748974B2 (ja) 2025-10-03
IL327564A (en) 2026-05-01
JP2023528896A (ja) 2023-07-06
CN121891333A (zh) 2026-04-21
KR102892626B1 (ko) 2025-11-28
CN116137811B (zh) 2026-01-09
CL2025002636A1 (es) 2025-11-28
AU2021285225A1 (en) 2023-01-19
AU2021285225B2 (en) 2026-06-04
US20260076950A1 (en) 2026-03-19

Similar Documents

Publication Publication Date Title
CL2024000373A1 (es) Compuesto inductor de la degradación de plk1 novedoso
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
CL2025002636A1 (es) Uso inhibidor de pde10 para tratamiento del síndrome de tourette (divisional de solicitud no. 202203400)
CR20220236A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
CL2022002919A1 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
CL2009000429A1 (es) Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer.
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
PE20191496A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
UY30004A1 (es) Metodos y kits para dosificar nucléosidos antivirales beta-d-2´, 3´-didehidro-2´, 3´- dideoxi-5-fluorocitidina
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
MX2023006751A (es) Nuevo derivado de camptotecina, composicion que comprende el mismo y su uso.
DOP2022000031A (es) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas
GEAP202616896A (en) Combinations for the treatment of cancer
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
EA201891050A1 (ru) Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2
CR20250160A (es) Compuestos n-(5-sustituido-[(1,3,4-tiadiazolil) o (1,3-tiazolil)](sustituido) carboxamida, composiciones farmacéuticas y métodos de preparación de los compuestos amida y de su uso
CO2022008690A2 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
MX2023015121A (es) Metodos de uso de inhibidores de aldosterona sintasa.
UY38972A (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
MX2025002228A (es) Metodos para el tratamiento o la profilaxis de la endometriosis
PE20240822A1 (es) Inhibidores de vmat2 y metodos de uso